Alvotech SA has announced a new collaboration with Dr. Reddy's Laboratories Ltd. to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda® (pembrolizumab), a widely used cancer treatment. This partnership will leverage the strengths of both companies in biosimilar development, aiming to expedite the process and expand global access to this critical medication. Both companies will share responsibilities and costs associated with the development and manufacturing of the biosimilar. The agreement marks a significant step in providing cost-effective biologic treatments to patients worldwide, particularly in the field of oncology, which is a focus area for Dr. Reddy's. Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.